J&J is your #1 Spinoff Buy for 2023

Article Excerpt

We’ve selected Johnson & Johnson as your #1 Spinoff Buy for 2023. The pharmaceutical giant is shifting its focus to its prescription drugs and medical device businesses. Under that plan, it will soon spin off its consumer products business as a separate, publicly traded firm called Kenvue. While pharmaceuticals and medical devices are riskier to develop, they promise faster sales growth and higher returns. Johnson & Johnson has gained 3% since it announced the split in November 2021, and should go higher as COVID-19’s strain on hospitals further eases. Kenvue’s outlook is also positive given that its well-known brands generate steady cash flows. JOHNSON & JOHNSON $170 is your #1 Spinoff Buy for 2023. The company (New York symbol JNJ; Consumer sector; Shares outstanding: 2.6 billion; Market cap: $442.0 billion; Dividend yield: 2.7%; Takeover Target Rating: Medium; www.jnj.com) is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. The company was founded in 1886 and is headquartered in New Brunswick, New Jersey. It operates through…